Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases.

Most primary immunodeficiency diseases (PIDDs) resulting in antibody deficiency require intravenous or subcutaneous immunoglobulin G (SCIG) replacement therapy. The flow and distribution of SCIG to the vasculature is impeded by the glycosaminoglycan hyaluronan in the extracellular matrix, which limits the infusion rate and volume per site, necessitating frequent infusions and multiple infusion sites. Hyaluronidase depolymerizes hyaluronan and is a spreading factor for injectable biologics. Recombinant human hyaluronidase (rHuPH20) increases SCIG absorption and dispersion. In patients with PIDD, SCIG facilitated with rHuPH20 (IGHy) has been shown to prevent infections, be well-tolerated and reduce infusion frequency and number of infusion sites as compared with conventional SCIG. This article reviews IGHy clinical studies and real-world practice data in patients with PIDD.

[1]  J. Casanova,et al.  The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies , 2017, Journal of Clinical Immunology.

[2]  S. Mercadal,et al.  Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. , 2017, The Lancet. Haematology.

[3]  Ivan K. Chinn,et al.  Update on the use of immunoglobulin in human disease: A review of evidence , 2017, The Journal of allergy and clinical immunology.

[4]  R. Wasserman,et al.  Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy , 2017, Journal of Clinical Immunology.

[5]  T. Harrer,et al.  Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies , 2016, Clinical and experimental immunology.

[6]  C. Ernst,et al.  P259 Retrospective review of needle length and clinical considerations during hyaluronidase-facilitated subcutaneous administration of immunoglobulin (IGHY) , 2016 .

[7]  C. Ernst,et al.  P255 Real-world pediatric experience with hyaluronidase-facilitated subcutaneous immunoglobulin (IGHY) infusion parameters , 2016 .

[8]  I. Hussain,et al.  Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America , 2016, Journal of Clinical Immunology.

[9]  J. Puck,et al.  Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability. , 2016, Immunotherapy.

[10]  J. Puck,et al.  Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency , 2016, Journal of Clinical Immunology.

[11]  Hosein Shabaninejad,et al.  A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis , 2016, Expert review of clinical immunology.

[12]  S. Hughes,et al.  Real-World Use of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IG) (IGHy) in Patients with Primary Immunodeficiency Disorders (PIDD) , 2016 .

[13]  É. Oksenhendler,et al.  The ratio of mean daily IgG increment/mean daily dose in immunoglobulin replacement therapy in primary antibody deficiencies. , 2015, The journal of allergy and clinical immunology. In practice.

[14]  J. Casanova,et al.  The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies , 2015, Journal of Clinical Immunology.

[15]  B. Sugarman,et al.  Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration , 2015, The AAPS Journal.

[16]  S. Bowen,et al.  Prevalence and Morbidity of Primary Immunodeficiency Diseases, United States 2001–2007 , 2014, Journal of Clinical Immunology.

[17]  R. Wasserman.  Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. , 2014, Immunotherapy.

[18]  S. Sondhi,et al.  Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment , 2014, Patient preference and adherence.

[19]  J. Orange,et al.  Global overview of primary immunodeficiencies: a report from Jeffrey Modell Centers worldwide focused on diagnosis, treatment, and discovery , 2014, Immunologic research.

[20]  C. Jackisch,et al.  Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase , 2013, British Journal of Cancer.

[21]  G. Freyer,et al.  Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer , 2013, OncoTargets and therapy.

[22]  J. Puck,et al.  Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. , 2012, The Journal of allergy and clinical immunology.

[23]  L. Kobrynski.  Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases , 2012, Biologics : targets & therapy.

[24]  R. Wasserman.  Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again , 2012, Journal of Clinical Immunology.

[25]  F. Drake,et al.  Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model , 2012, Drug Delivery and Translational Research.

[26]  T. Baba,et al.  Functional characterization of double-knockout mouse sperm lacking SPAM1 and ACR or SPAM1 and PRSS21 in fertilization. , 2012, The Journal of reproduction and development.

[27]  J. Casanova,et al.  Primary Immunodeficiency Diseases Worldwide: More Common than Generally Thought , 2012, Journal of Clinical Immunology.

[28]  M. Berger.  Incidence of Infection is Inversely Related to Steady-State (Trough) Serum IgG Level in Studies of Subcutaneous IgG in PIDD , 2011, Journal of Clinical Immunology.

[29]  W. Grossman,et al.  Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease , 2011, Journal of Clinical Immunology.

[30]  Christine J. Bryson,et al.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges. , 2010, Self/nonself.

[31]  P. O'Connor,et al.  Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models , 2010, Molecular Cancer Therapeutics.

[32]  J. Orange,et al.  Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. , 2010, Clinical immunology.

[33]  Kathleen C. Williams,et al.  Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. , 2010, Clinical immunology.

[34]  H. Ochs,et al.  Subcutaneous immunoglobulin: opportunities and outlook , 2009, Clinical and experimental immunology.

[35]  V. Bonagura,et al.  Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. , 2008, The Journal of allergy and clinical immunology.

[36]  D. Kennard,et al.  Assessment and Implication of the Allergic Sensitivity to a Single Dose of Recombinant Human Hyaluronidase Injection: A Double‐blind, Placebo‐controlled Clinical Trial , 2007, Journal of infusion nursing : the official publication of the Infusion Nurses Society.

[37]  G. Frost.  Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration , 2007, Expert opinion on drug delivery.

[38]  J S Patton,et al.  A recombinant human enzyme for enhanced interstitial transport of therapeutics. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[39]  C. Hardy,et al.  Assessment of contraceptive vaccines based on recombinant mouse sperm protein PH20. , 2004, Reproduction.

[40]  M. Ikawa,et al.  Mouse Sperm Lacking Cell Surface Hyaluronidase PH-20 Can Pass through the Layer of Cumulus Cells and Fertilize the Egg* , 2002, The Journal of Biological Chemistry.

[41]  K. Beagley,et al.  Restricted Entry of IgG into Male and Female Rabbit Reproductive Ducts Following Immunization with Recombinant Rabbit PH‐20 , 2002, American journal of reproductive immunology.

[42]  P. Primakoff,et al.  cDNA cloning reveals the molecular structure of a sperm surface protein, PH-20, involved in sperm-egg adhesion and the wide distribution of its gene among mammals , 1990, The Journal of cell biology.

[43]  J. Denburg,et al.  Hypogammaglobulinemia: therapeutic rationale. , 1987, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[44]  Henry Levison,et al.  HIGH-DOSE VERSUS LOW-DOSE INTRAVENOUS IMMUNOGLOBULIN IN HYPOGAMMAGLOBULINAEMIA AND CHRONIC LUNG DISEASE , 1987, The Lancet.

[45]  F. Duran-Reynals,et al.  THE EFFECT OF EXTRACTS OF CERTAIN ORGANS FROM NORMAL AND IMMUNIZED ANIMALS ON THE INFECTING POWER OF VACCINE VIRUS , 1929, The Journal of experimental medicine.